C-Reactive Protein And Plasminogen Activator Inhibitor-1 A Cardiovascular Risk Predictor In Women With Polycystic Ovarian Syndrome
Keywords:
PCOS, TSH, LH, CVD, PAI-1Abstract
Background: A diverse endocrine condition known as polycystic ovarian syndrome (PCOS) affects 6 to 10% of women of reproductive age. Menstrual irregularity, hyperandrogenism, insulin resistance, anovulatory infertility, and other endocrinopathy known as PCOS are some of its symptoms. There is mounting evidence that cardiovascular disease is becoming more common (CVD) in PCOS females.
Material & method: Our study was prospective case-control research 75 healthy women were included as BMI-matched controls since they had no male-type baldness, hirsutism, acne, or hirsutism. hyperandrogenism symptoms or a family history of PCOS, as well as normal menstrual periods.
Result: In present study when compared to control patients, PCOS patients had substantially higher mean blood levels of TSH, FSH, LH, PRL, hs-CRP, and PAI-1 (p 0.000). In comparison to the healthy controls, the mean fasting blood sugar was considerably higher (p 0.01). 54.16% of all patients had hs-CRP levels more than 3 mg/L, placing them at an increased risk of cardiovascular disease.
Conclusion: Women with the lean phenotype of PCOS have multiple metabolic problems, including abdominal obesity, dyslipidemia, hyperandrogenemia, and insulin resistance. The conclusions of the According to the study, a milieu of continual low-grade inflammation caused by macrophage infiltration in peripheral organs exacerbates metabolic derangements and cardiovascular risk.
Downloads
Metrics
References
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89(06): 2745–2749
Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352 (12):1223–1236
Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333(13): 853–861
Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord 2018;17(02):277–285
Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29(02):181–191
Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998; 51(05):415–422
Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20(11):2414–2421
Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term followup: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52 (05):595–600
Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol 2009;2(04):232–239
Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103(21):2531–2534
Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342(24):1792–1801
Alessi M-C, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26(10):2200–2207
Schneider DJ, Sobel BE. PAI-1 and diabetes: a journey from the bench to the bedside. Diabetes Care 2012;35(10):1961–1967
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81(01):19–25
Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012; 18(06):618–637
Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86(06):2453–2455
Oh JY, Lee J-A, Lee H, Oh J-Y, Sung Y-A, Chung H. Serum C-reactive protein levels in normal-weight polycystic ovary syndrome. Korean J Intern Med (Korean Assoc Intern Med) 2009;24(04): 350–355
Ding T, Hardiman PJ, Petersen I, Wang F-F, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and metanalysis. Oncotarget 2017;8(56):96351–96358
Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol 2014;12(01):89
Xia C, Li R, Zhang S, et al. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr 2012;66(09):1035–1038
Wiltgen D, Benedetto IG, Mastella LS, Spritzer PM. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod 2009;24(07): 1726–1731
Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 2009;160(05):785–790
Muscogiuri G, Sorice GP, Mezza T, et al. High-normal TSH values in obesity: is it insulin resistance or adipose tissue’s guilt? Obesity (Silver Spring) 2013;21(01):101–106
Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gärtner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004;150(03):363–369
Fairweather D, Rose NR. Women and autoimmune diseases. Emerg Infect Dis 2004;10(11):2005–2011 35 González F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91(04):1508–1512
González F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012;77(04):300–305
Keskin Kurt R, Okyay AG, Hakverdi AU, et al. The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case-control study. Arch Gynecol Obstet 2014;290(02):315–319
Makedos A, Goulis DG, Arvanitidou M, et al. Increased serum Creactive protein levels in normal weight women with polycystic ovary syndrome. Hippokratia 2011;15(04):323–326
Keskin Kurt R, Okyay AG, Hakverdi AU, et al. The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case-control study. Arch Gynecol Obstet 2014;290(02):315–319
Kim JW, Han JE, Kim YS, Won HJ, Yoon TK, Lee WS. High sensitivity C-reactive protein and its relationship with impaired glucose.
Ghatnatti V, Patil S, Kour H. Assessment of clinical, biochemical, and hormonal profile of lean versus overweight polycystic ovarian syndrome patients: a cross-sectional study. J Intern Med 2022; 10(01):13–16
Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996;45(05): 623–629.
Orio F Jr., Palomba S, Cascella T, et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online 2004;9(05): 505–510
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
